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Genome-wide association studies have identiﬁed a great number of non-coding risk variants
for colorectal cancer (CRC). To date, the majority of these variants have not been functionally
studied. Identiﬁcation of allele-speciﬁc transcription factor (TF) binding is of great importance
to understand regulatory consequences of such variants. A recently developed
proteome-wide analysis of disease-associated SNPs (PWAS) enables identiﬁcation of
TF-DNA interactions in an unbiased manner. Here we perform a large-scale PWAS study to
comprehensively characterize TF-binding landscape that is associated with CRC, which
identiﬁes 731 allele-speciﬁc TF binding at 116 CRC risk loci. This screen identiﬁes the A-allele
of rs1800734 within the promoter region of MLH1 as perturbing the binding of TFAP4
and consequently increasing DCLK3 expression through a long-range interaction,
which promotes cancer malignancy through enhancing expression of the genes related to
epithelial-to-mesenchymal transition.
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A
n individual’s risk to develop colorectal cancer (CRC) is
affected by a broad spectrum of genetic variants that
abolish the functions and/or alter the expression of target
genes. In CRC, two types of genetic variants have been extensively
discussed to contribute to disease onset and progression:
(1) protein-coding mutations and (2) non-coding variants, in
particular in DNA regulatory elements. To date, the majority of
studies have focused on protein-coding mutations. Key coding
mutations such as APC/CTNNB1, KRAS/BRAF, PIK3CA, TP53
and SMAD4 have been intensively characterized1. However, even
though a great number of non-coding risk variants for CRC have
been identiﬁed in genome-wide association studies (GWAS)2–9,
their molecular functions have rarely been determined.
Functional genetic variants in distal DNA regulatory elements
may alter transcription networks in several ways such as by
affecting transcription factor (TF) binding. Single-nucleotide
polymorphisms (SNPs) within TF-binding sites may affect the
local chromatin accessibility10–12 and/or alter the expression
of gene targets through mediating different chromatin
interactions13–15. Therefore, identiﬁcation of variant-speciﬁc TF
interactors is of great importance to understand regulatory
consequences of the variants. However, DNA oriented methods
such as DNase I sequencing (DNase I-seq)16, systematic evolution
of ligands by exponential enrichment sequencing17 and
chromatin immunoprecipitation with massively parallel DNA
sequencing (ChIP-seq)18 are biased by DNA motif knowledge or
limited by the availability of antibodies, resulting in a biased
identiﬁcation of TF-binding dynamics at disease-associated loci.
A recently developed proteome-wide analysis of disease-
associated SNPs (PWAS) enables to identify DNA–TF
interactions in an unbiased manner19. A similar approach has
been used to characterize a protein–DNA interaction map for
ultra-conserved elements20. Therefore, we performed a large-scale
PWAS study to comprehensively understand TF-binding
landscape related to CRC.
As the outcome from our PWAS screen, we further
investigated the functions of a SNP located in the promoter
region of MLH1 gene (MLH1-93G4A or rs1800734), which has
been associated with the risk of several cancer types including
CRC9,21,22, endometrial cancer23, glioblastoma24 and lung
cancer25. Here we identiﬁed a molecular function of this SNP
in promoting cancer malignancy through a novel gene target
named DCLK3.
Results
PWAS identiﬁed TF occupancy switching at the 116 loci. We
selected 116 SNPs associated with CRC risk2–9 for PWAS analysis
including the following: (1) typed and imputed GWAS signiﬁcant
SNPs (for imputed SNPs, linkage disequilibrium (LD) r2Z0.2)
from 8q24.21 (MYC-335), 15q13.3 (GREM1) and 18q21.1
(SMAD7); (2) SNPs with functional evidence rs16969681/
15q13.3 (ref. 26), rs58920878/18q21.1 (ref. 27), rs16888589/
8q23.3 (ref. 28) and rs4444235/14q22.2 (ref. 29); (3) 3 SNPs from
3p22.2 (MLH1 region)9; and (4) GWAS signiﬁcant SNPs in
DNase I-seq peaks in minimal one of 15 fetal large intestine
tissues and 12 CRC cell lines (Supplementary Data 1). The PWAS
analysis identiﬁed 731 TF-binding alterations between reference
(Ref) and alternate (Alt) alleles (Po0.01, A/B signiﬁcance test)
(Supplementary Data 2). Compared with proteome data, TF–
DNA interactome data showed a clear enrichment for TFs
(Supplementary Fig. 1a) and the altered binding events mediated
by known TFs (Supplementary Data 3) showed stronger allele
preference than other interactions (P¼ 4.4 10 6, Mann–
Whitney U-test) (Supplementary Fig. 1b). Overlay of the
pulldowns showed a consistent allele preference between two
replicate experiments (Supplementary Fig. 1c). Many of the 731
TFs showed 48-fold afﬁnity to one of the alleles at these loci
(Fig. 1a), for example, TFAP4 at rs1800734 and RUNX1/RUNX2/
CBFB at rs1741640. As expected, top pathways associated with
the 731 TFs included key CRC drivers such as WNT and
transforming growth factor-b pathways (Fig. 1b).
It is well-known that DNase I-hypersensitive sites coincide with
regulatory elements and are the hotspots for TF binding16. To
better predict in vivo TF binding, it is necessary to consider the
hypersensitivity of tested regions. Therefore, we ranked all the
SNP-TF interactions based on PWAS fold change (Ref/Alt allele)
and DNase I hypersensitivity (DHS) of the SNP loci. A total of 27
signiﬁcant allele-speciﬁc SNP–TF binding events were considered
to be important (Fig. 1c and Supplementary Table 1). Many
selected TF–SNP interactions (Fig. 1d and Supplementary Fig. 1d)
were validated using ChIP-seq data (Supplementary Fig. 1e). Based
on this selection, the top candidate SNP is rs1800734 (MLH1 -93
G4A) in the 50-untranslated region (UTR) region of MLH1 gene.
Therefore, we decided to focus on this SNP.
PWAS identiﬁed speciﬁc interactors of rs1800734. Our PWAS
screen identiﬁed TFAP4 as an allele-speciﬁc interactor with an
almost 16-fold higher afﬁnity for G-allele, whereas ELF1 showed
higher afﬁnity for the A-allele of rs1800734 in LoVo cells
(Fig. 1d). The A-allele abolishes TFAP4 binding due to a
point mutation at the last position of the E-box (Fig. 2a),
which simultaneously creates an E26 transformation-speciﬁc
(ETS) family binding motif (Supplementary Fig. 2a). We corro-
borated and extended this ﬁnding by label-free-based DNA
pulldown with SNU175 and COLO320 extracts (Fig. 2b and
supplementary Fig. 2b). Notably, other basic helix-loop-helix
(bHLH) and ETS family members also displayed allele-
speciﬁc binding, including MYC and ELF2 (Supplementary
Fig. 2b,c), indicating that these TFs can compete with TFAP4
and ELF1 at this locus. Using ChIP-seq as an orthogonal
technique, we validated TFAP4 and ELF1 binding at the
rs1800734 in the SNU175 and COLO320, cell lines heterozygous
for this locus. Consistent with PWAS, TFAP4 ChIP-seq showed a
dominant preference for G-allele binding in the two cell lines
(Fig. 2c). ELF1 did not show signiﬁcant allele-binding preference
(Supplementary Fig. 2d), which may be due to the competitive
binding interference by other ETS proteins.
DCLK3 is a novel target of rs1800734. Given the position of the
SNP in the promoter of MLH1, we further investigated whether
predisposition of rs1800734 in CRC is due to DNA methylation of
MLH1 promoter as proposed9,30. We tested hypersensitivity and
transcription of G- and A-allele in the two heterozygous cell lines,
which showed the two alleles are equally accessible and transcribed
(Fig. 2d). The neighbouring gene EPM2AIP1, also reported to be
regulated by rs1800734 (ref. 31), was similarly unaffected by
rs1800734 (Fig. 2d). Hence, we conclude that rs1800734 does not
result in allele-speciﬁc epigenetic silencing of either MLH1 or
EPM2AIP1 in these cell lines. We sought to conﬁrm our
observation in the Systems Biology of Colorectal Cancer
(SYSCOL) cohort of paired healthy and tumour tissues (healthy:
n¼ 288, tumour: ¼ 289). A strong expression quantitative trait
loci (eQTL) between rs1800734 and MLH1 was observed in the
healthy tissues (P¼ 0.001, linear regression model) but the A-allele
was associated with increased MLH1 expression. This eQTL was
lost in the tumours and remained only a weak association in
microsatellite stable (MSS) tumours (P¼ 0.025, n¼ 236, linear
regression model) (Supplementary Fig. 3a). Intriguingly, we
identiﬁed a correlation between rs1800734 and DCLK3
expression in the healthy (P¼ 0.029, linear regression model)
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Figure 1 | PWAS screen systematically identiﬁed allele-speciﬁc TF binding at the selected CRC risk loci. (a) Allele-speciﬁc binding of the 731 candidate
TFs at the 116 CRC risk loci. Chromatin environment of the 116 SNPs was described by DHS of these loci in the 15 fetal large intestine tissues and 12 CRC
cell lines, and histone modiﬁcations (H3K4me3, H3K4me1 and H3K27ac) within±1 kb regions around these loci in the LoVo and HCT116 cell lines. The TFs
with P-valueo10 30 and absolute Log2(fold change)43 was listed in the bubble plot. Bubble size represents  Log10(P-values) of the interactors in the
pull-down screen (n¼ 2 pulldowns per SNP, P-values: A/B signiﬁcance test). (b) Pathway annotation of the 731 TFs (HR, gonadotropin-releasing hormone
receptor pathway; WNT/PDGF/CCKR/transforming growth factor (TGF)-b, Wnt/PDGF/Cholecystokinin/TGF-b signalling pathways). (c) TF–SNP
interactions ranked by fold changes in the PWAS screen and DHS at the SNP loci. Bubble size indicates the  Log10(P-values) of the TF–SNP interactions
(n¼ 2 pulldowns per SNP, red and blue bubbles: P-valueo0.05, Z-test). (d) The top three candidate TF–SNP interactions (n¼ 2 pulldowns per SNP, red and
blue dots: P-valueso0.01, A/B signiﬁcance test).
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and tumour (P¼ 0.031, linear regression model) samples, and this
association was highly signiﬁcant in the MSS patients (P¼ 0.004,
linear regression model) (Fig. 2e), indicating this locus may act as a
distal enhancer and regulate DCLK3.
The A-allele positively regulates transcription of DCLK3. To
establish the functional relation between rs1800734 and DCLK3
expression, two isogenic cell lines homozygous for G- or A-allele
were generated from COLO320 using CRISPR-CAS9 technique
(Fig. 3a). Successful targeting of rs1800734 was conﬁrmed by
Sanger sequencing (Fig. 3b). No other mutation was observed in
the surrounding region. ChIP–quantitative PCR (qPCR) con-
ﬁrmed higher TFAP4 binding to the G-allele (Supplementary
Fig. 3b) and the level of MLH1 and EPM2AIP1 transcription was
identical in the three isogenic lines (Supplementary Fig. 3c).
Importantly, the eQTL association between rs1800734 and
DCLK3 expression was replicated and a ﬁvefold difference in
DCLK3 expression was observed between G- and A-homozygotes
(Fig. 3c). By sequencing the inter-exonic reverse transcriptase–
qPCR products of DCLK3, we conﬁrmed the transcription of
DCLK3 in these cell lines (Supplementary Fig. 3d).
rs1800734 regulates DCLK3 through long-range interactions.
A capture Hi-C study has suggested that rs3806624 in the
promoter of EOMES affects AZI2, a gene 640 kbp downstream to
this SNP, through a long-range chromatin interaction14. A similar
constellation may apply to rs1800734. Therefore, Circularized
Chromosome Conformation Capture with massively parallel
DNA sequencing (4C-seq) was employed to search for long-range
interactions between rs1800734 and other potential targets in the
three isogenic cell lines. Using rs1800734 as a view point, a
signiﬁcantly enhanced interaction was observed in A-homozygote
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Figure 2 | Identiﬁcation of allele-speciﬁc interactors for rs1800734 and its potential gene targets. (a) Motif analysis interpreted that A-allele of the loci
perturbs E-box motif. (b) The speciﬁc binding of TFAP4 (P1¼ 2.0 10 6, P2¼ 3.1 10 5, P3¼ 7.8 10 5, Student’s t-test) and ELF1 (P1¼ 2.1 104,
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(d) the local chromatin accessibility and the expression of two cis-regulated genes (MLH1 and EPM2AIP1) (G (G-allele) and A (A-allele) of rs1800734,
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with DCLK3 region (Fig. 3d). Increased interactions were found
in the promoter and 30-UTR region of DCLK3 in two
independent experiments (Fig. 3e) and, in addition, the 30-UTR
interaction appeared to increase chromatin accessibility (Fig. 3f).
In conclusion, the A-allele of rs1800734 increases the DCLK3
transcription through increased chromatin interaction and
enhanced chromatin accessibility.
DCLK3 is a potential oncogenic and tumour progressive factor.
DCLK3 is one of three doublecortin-like kinases (DCLK1,
DCLK2 and DCLK3). In this family, DCLK1 has been shown to
be a cancer stem cell marker in intestinal tumours32. The
molecular function of the DCLK3 has not been characterized in
depth. We therefore performed gene set enrichment analysis
(GSEA) to identify DCLK3-associated gene sets in the SYSCOL
RNA sequencing (RNA-seq) cohort. Interestingly, we found that
epithelial-to-mesenchymal transition (EMT)-related genes were
highly correlated to the expression of DCLK3 in the healthy
tissues (normalized enrichment score (NES)¼ 2.50), which was
enhanced in the tumour samples (NES¼ 3.10) (Fig. 4a and
Supplementary Table 2). Using a cutoff of NES at 2.00, we also
identiﬁed gene sets that are preferentially enriched in the healthy
versus tumour tissues (Supplementary Table 2), for example
‘MYC targets’ and ‘G2/M checkpoint’ gene sets were enriched in
the healthy tissue, whereas ‘Angiogenensis’ and ‘tumor necrosis
factor alpha (TNFA) signalling via nuclear factor–kB’ gene sets
were enriched in the tumour tissues (Fig. 4a). As expected,
common EMT markers such as CALD1, FN1, SNAI1, SNAI2,
TWIST1, VIM, ZEB1 and ZEB2 were highly signiﬁcantly co-
expressed with DCLK3 in the tumours (Fig. 4a), indicating that
DCLK3 is an EMT regulator. Furthermore, we observed elevated
DCLK3 expression in the tumour compared with healthy tissues
(P¼ 2.2 10 16, Mann–Whitney U-test) (Fig. 4b), but no
difference between the microsatellite instable (MSI) and
microsatellite stable (MSS) tumours (Fig. 4b). Interestingly, this
elevation appeared to be correlated with the CRC progression:
DCLK3 expression was at a comparable level in the healthy and
adenoma tissues, and increased B2-fold in the stage I tumours
and remained at this level during tumour malignancy
(P¼ 2.2 10 16, Kruskal–Wallis test) (Fig. 4b). Therefore,
DCLK3 may promote EMT events and consequently drive
tumour malignancy.
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Discussion
Our study generated the ﬁrst TF–SNP interaction map at
presumed disease-relevant loci of CRC and determined
TF-binding occupancy at the 116 upmost relevant CRC risk loci.
Together with GWAS and epigenetic proﬁling data, our PWAS
screens provide a comprehensive TF-binding landscape of these
loci and yielded candidate interactions for further functional
investigations (Fig. 1a,c,d and Supplementary Fig. 1d,e). As an
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correlated cancer hallmark gene sets. EMT and oxidative phosphorylation-associated gene sets were highly signiﬁcantly associated with the DCLK3
expression in both healthy and tumour tissues. In addition, some DCLK3-associated gene sets showed healthy or tumour tissue speciﬁcity (P-values were
calculated in GSEA based on Pearson’s correlation). The expression of key EMT markers showed good correlation with the DCLK3 expression. (b) The
DCLK3 expression was preferentially elevated in the tumours and especially the malignant tissues. However, we did not observe a clear difference between
MSI and MSS tumours (P-values: Mann–whitney U-test (MW test) and Kruskal–Wallis test (KW test)). (c) A proposed model describing how rs1800734
modiﬁes the risk of CRC malignancy. TFAP4 and ETS family members speciﬁcally bind to the protective G- or risk A-allele, respectively. The rs1800734-ETS
interaction increases the enhancer activity of the rs1800734 locus and enhances the expression of DCLK3 through an increased chromatin interaction.
Cancer cells with the elevated DCLK3 expression undergo EMT and therefore metastasize to distal sites.
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alternative tool to investigate allele-speciﬁc TF-binding events,
the PWAS approach shows several advantages over the DNA-
centric methods. In contrast to ChIP-seq technique, PWAS-based
identiﬁcation is a hypothesis-free approach, which does not
require any knowledge on the possible binding TFs at risk loci. In
addition, application of PWAS approach is not limited by the
availability of high-quality ChIP-grade antibodies. Even though
large ChIP-seq data sets have been generated18,33, these data
nevertheless cover only a small proportion of the entire repertoire
of TFs. Other DNA-centric methods, such as DNase I-seq or
assay for transposase-accessible chromatin with high throughput
sequencing (ATAC-seq), are only capable of identifying DNA
motifs present at risk loci, which makes it difﬁcult to predict
actual binding TF(s) from a family sharing similar motifs in a
speciﬁc cell type. The outcome of PWAS is a reﬂection of TF
abundance, TF ability to bind to the sequence (afﬁnity), as well as
synergistic and antagonist effects due to binding of other TFs to
adjacent or overlapping sequences. Therefore, actual binding TFs
in a given cell type can be predicted using PWAS method. In
addition, PWAS approach also help to identify binding TFs at the
loci only partially matching consensus motif sequences and
therefore cannot be predicted by motif prediction-based methods.
Based on the PWAS screen, we investigated in great depths for
a well-known CRC-associated SNP: MLH1-93G4A or
rs1800734. It has been postulated that A-allele (risk allele) of
the rs1800734 recruits repressive TFs, which subsequently results
in promoter methylation of the MLH1 gene9,30, supported by an
association between the A-allele of the rs1800734 and promoter
methylation34 or decreased expression of MLH1 (refs 35,36).
However, Suter et al.37 showed contradictory results that A-allele
of this SNP is associated with lower promoter methylation and
higher transcription of MLH1. Our results suggested that TFAP4
preferentially binds to T-allele of the rs1800734 but does not
change promoter accessibility and transcription of MLH1.
Analysis of the SYSCOL cohort strengthened the ﬁndings in the
cell lines (Supplementary Fig. 3a) and identiﬁed a new gene target
DCLK3 in the MSS patients (Fig. 2e). Furthermore, CRISPR-
CAS9 facilitated to generate fully comparable isogenic lines
carrying G- or A-point mutation at rs1800734 locus. Therefore,
mild changes in chromatin interaction, accessibility and
consequently gene expression can be monitored by different
genomic techniques. It has been shown that some functional
SNPs in enhancer regions result in subtle changes in expression of
their target genes, for example, the G-allele of rs356168 increased
SNCA expression by 1.06 times in neurons and 1.18 times in
neuron precursors38. Hence, accurate genome editing is required
to distinguish these subtle changes. Using this model system, an
increased DCLK3 transcription was detected in the A/A
homozygous line (Fig. 3c), which is due to increased chromatin
interaction between the two locus and consequently elevated
chromatin accessibility in the DCLK3 region (Fig. 3d,e,f). These
data conﬁrmed that rs1800734, even though locates in the
promoter region of MLH1, serves as a distal enhancer for the
DCLK3 gene. Notably, our ﬁndings are based on the genetic
background of MSS tumours, which is likely to be responsible for
the contradiction between our data and some of the literature.
Moreover, DCLK3 has been shown to be associated with EMT
process in this study (Fig. 4a). Although the full molecular
mechanism of DCLK3 in regulating EMT has not been
characterized, this protein has been shown to directly interact
with CDK5 (ref. 39) and the latter promotes breast
cancer metastasis through regulating transforming growth
factor-b1-induced EMT40. Alternatively, CDK5 also prevents
phosphorylation and degradation of a EMT regulator CALD1
(ref. 41) and hence promotes the EMT process42. Furthermore,
DCLK3 may perform a similar function as another doublecortin-
like kinase DCLK1, as it possesses the similar protein kinase
domain and one of the two doublecortin domains43 as DCLK1. In
intestinal tumours, DCLK1 often co-expresses with LGR5 at crypt
base and DCLK1þLGR5þ stem cells are able to continuously
produce tumour progeny under the APCþ / mice32. A further
study showed that DCLK1þ cells are long-lived and quiescent
population, which is only activated and display carcinogenesis
properties on oncogenic mutation and tissue injury44.
In summary, we conclude that ETS family TFs preferentially
bind to the A-allele of rs1800734 and increase chromatin
interaction between the rs1800734 locus and the DCLK3 region.
This enhanced chromatin interaction in turn increases the
expression of DCLK3. Consequently, the risk of tumour
metastasis is increased due to increased EMT feature of cancer
cells (Fig. 4c). In addition, our study systematically identiﬁed
changes in TF binding at regulatory CRC risk loci, which provide
candidates for functional follow-up.
Methods
Cell culture and extraction of nuclear soluble fraction. Human CRC cell lines
were cultured in DMEM or RPMI medium supplemented with 10% fetal bovine,
100Uml 1 penicillin and 100 mgml 1 streptomycin. LoVo and SNU175 cell lines
were purchased from American Type Culture Collection and Korean Cell Line
Bank (KCLB), respectively. COLO320 cell line was a generous gift of Dr Riccardo
Fodde (Erasmus Medical Center Rotterdam, The Netherlands), which is originally
from American Type Culture Collection. The authenticity of the cell lines were
conﬁrmed using microsatellite short tandem repeat (STR) assay by the suppliers of
the cell lines. Mycoplasma infection was routinely tested in-house, to ensure that all
the cell lines used for this study were free of mycoplasma contamination. Nuclear
soluble fraction of LoVo, SNU175 and COLO320 was performed using a published
protocol45. Protein concentration of the obtained nuclear extract was quantiﬁed
using Branford assay. Each of the 3mg extract (12 individual DNA pulldowns) was
aliquoted, snap-frozen in liquid nitrogen and stored at  80 C.
High-throughput DNA pulldown. High-throughput DNA pull-down experiments
was performed on 96-well ﬁlter plate format using our published method46 with
minor modiﬁcations. To synthesize biotinylated double-stranded DNA (dsDNA)
oligo, we attached a non-genomic 15 bp sequence at the 30-end of the anti-sense
strands. Subsequently, a reverse complement biotinylated primer was used to
extend single-stranded DNA templates into dsDNA oligos. For each synthesis,
150 pmol of the biotinylated primer and 200 pmol template were subjected to a
PCR reaction using Herculase II Fusion Enzyme kit under the following conditions:
95 C for 3min; thermocycling (n¼ 20) at 95 C for 1min, 45 C for 1min and
72 C for 1min; 72 C for 3min; inﬁnite hold at 12 C. Brieﬂy, high-throughput
DNA pulldown was performed using a Multiscreen ﬁlter plate with 1.2 mm pores
(Millipore, MSBVN1210). The biotinylated dsDNA oligos were immobilized on
20 ml of high-performance streptavidin sepharose (GE Healthcare, 17511301).
Two-hundred and ﬁfty micrograms of nuclear extracts and 15 mg of competitors
(5 mg of poly(deoxyinosinic-deoxycytidylic) acid sodium salt (Sigma-Aldrich,
P4929), poly(deoxyadenylic-thymidylic) acid sodium salt (Sigma-Aldrich, P0883)
and Bakers yeast RNA (Sigma-Aldrich, R6750)) were added and incubated with
immobilized oligos for 1.5 h at 4 C on a plate shaker for each of the pull-down
experiments. The components of the competitors were sonicated into B300 bp
fragments before use. The proteins unbound to DNA oligos were washed off using
different washing buffers and the bound TFs were on-bead digested overnight
using trypsin/lysC. The pull-down duplicates underwent dimethyl label swapping
and measured by nanoscale liquid chromatography tandem mass spectrometry
(LC–MS/MS) in a 2 h gradient.
Nuclear extract proteome. Deep proteome proﬁle was generated from the nuclear
extracts used for the pull-down experiments. An absolute quantiﬁcation strategy
was taken following a published method46. In brief, 3.3 mg of universal protein
standard 2 (Sigma-Aldrich) and 10 mg of the nuclear extracts were mixed and
subjected to a ﬁlter-aided sample preparation digestion. In parallel, 30 mg of the
nuclear extracts were also digested using the ﬁlter-aided sample preparation
protocol and subsequently separated into six fractions using strong anion
exchange. The universal protein standard 2 sample and the fractions was puriﬁed
on C18 stage tips and proﬁled by nanoscale LC–MS/MS in a 4 h gradient.
DNase I sequencing. DNase I library of the LoVo cell line was constructed
following a reported protocol with some minor modiﬁcations47. In short, 5 106
nuclei were isolated using a buffer (15mM Tris-HCl pH 8.0, 15mM NaCl, 60mM
KCl, 1mM EDTA pH 8.0, 0.5mM EGTA pH 8.0 and 0.5mM Spermidine)
supplemented with 0.05% IGEPAL CA-630 detergent. Subsequently, the isolated
nuclei were digested with 80U DNase I (Sigma-Aldrich, D4527) for 3min and the
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digestion was quenched by a stop buffer (50mM Tris-HCl pH 8.0, 100mM NaCl,
0.1% SDS, 100mM EDTA pH 8.0, 1mM Spermidine and 0.3mM Spermine). A 9%
Sucrose gradient was applied to fractionate the samples for 24 h at 25,000 r.p.m. at
16 C and the fractions with o1 kb fragments were further puriﬁed and prepared
according to the Illumina library preparation protocol.
DNase I library of other cell lines were prepared using a published protocol18 as
described below. The cell lines were harvested under the conﬂuence of 60% and
washed with PBS. Nuclei were isolated with RSB lysis buffer (10mM Tris-Cl
pH 7.4, 10mM NaCl, 3mM MgCl2, 0.1% IGEPAL CA-630) at 4 C for 10min.
Then the nuclei were treated with 0.12 unit of DNase I (Roche) in the provided
buffer at 37 C for 15min before being quenched by 50mM of EDTA. Following
RNase A (Sigma) treatment at 37 C for 15min, proteinase K (NEB) was added for
an additional hour at 56 C. DNA was extracted using phenol:chloroform:
isoamylalcohol. Agarose Gel (2%) electrophoresis was applied to separate the
released fragments (B100 bp) that were puriﬁed (Qiagen, MinElute Gel Extraction
Kit), followed by Illumina TruSeq library preparation and Sequencing (HiSeq2000).
ChIP-seq and ChIP–qPCR analysis. ChIP assays were performed following a
standard protocol. Cell lines were cross-linked by a ﬁnal concentration of 1%
paraformaldehyde for 10min and subsequently cross-linking reaction was
quenched using 1.5M glycine. The harvested cell lines were then lysed and
sonicated to obtain B300 bp chromatin using Bioruptor Plus sonication device
(Diagenode). The sonicated chromatin was pre-cleared by Protein A/G magetic
beads (ThermoFisher Scientiﬁc, 88802) and then incubated together with antibody
conjuncated beads overnight at 4 C. Antibodies against H3K27ac (Diagenode,
C15410196, 1 mg per ChIP assay), TFAP4 (Santa Cruz Biotechnology, sc-18593X,
6 mg per ChIP assay) and ELF1 (Santa Cruz Biotechnology, sc-631X, 4 mg per ChIP
assay) were used in our ChIP experiments. Posterior to the incubation, captured
chromatin was washed, eluted and de-crosslinked. Resulted DNA fragments were
puriﬁed and prepared according to Illumina library preparation (H3K27ac ChIP)
or KAPA Hyper Prep (TFAP4 and ELF1 ChIP) protocols before sequecning, or
directly quantiﬁed using SYBR Green-based qPCR assays (Supplementary Table 3).
ATAC-seq analysis. ATAC libraries of the SNU175 and COLO320 cell lines were
prepared by a documented protocol48 with some modiﬁcations. In brief, nuclei
were isolated using a lysis buffer consisting of 10mM Tris-HCl pH 7.5, 10mM
NaCl, 3mM MgCl2 and 0.1% IGEPAL CA-630 detergent and then tagmentated49
using 2 ml of Tn5 transposase and 12.5 ul 2 TD buffer (Illumina, Nextera DNA
Library Preparation Kit). The resulted DNA fragments underwent two sequential
nine-cycle PCR ampliﬁcation, and in between two PCR reactions the libraries were
selected for o600 bp fragments using SPRI beads. The ﬁnal PCR products were
puriﬁed and quantiﬁed by KAPA Library Quantiﬁcation Kits before sequencing.
Targeted RNA-seq and reverse transcriptase–qPCR. Total RNA was isolated
from the SNU175 and COLO320 cell lines using a TRIzol reagent (ThermoFisher
Scientiﬁc, 15596018) based method. The yielded RNA was treated using DNase and
then reversely transcribed into cDNA using random hexamers (ThermoFisher
Scientiﬁc, SO142). The cDNA was ampliﬁed using targeted primers and followed
by standard KAPA Hyper Prep protocols, or directly quantiﬁed using SYBR
Green-based qPCR assays (Supplementary Table 3).
CRISPR-CAS9-based SNP editing. CRISPR-CAS9 based SNP editing were per-
formed according to a previously reported method50. Single guide RNAs (sgRNAs)
were designed using an online tool (http://crispr.mit.edu/) and double-nicking
strategy was taken to reduce undesirable off-target mutagenesis. The sgRNAs were
then cloned into a U6-driven plasmid containing a green ﬂuorescent protein (GFP)
marker and the D10A mutant Cas9 nickase (Addgene, pSpCas9n(BB)-2A-GFP,
Plasmid 48140). The plasmid was then transformed into the DH5a competent
Escherichia coli strain and the products were puriﬁed for transfection.
Subsequently, two sgRNAs (400 ng each) and a 199 bp single-stranded
oligonucleotides (10 pmol single-stranded oligo donors/ssODNs (ssODNs),
possessing G or A point mutations at the rs1800734 locus) were co-transfected into
COLO320 cell lines following a standard lipofectamine LTX Reagent protocol
(ThermoFisher Scientiﬁc, 15338100). FACS analysis was used to sort 192 GFP-
positive cells per cell line (G or A point mutations) into 96-well plates in 36 h after
the transfection. In parallel, a wild-type cell line was treated in the same manner by
without using sgRNAs, and this mocked cell line was then sorted by FACS and
served as the control. The desirable genotype at the rs1800734 was conﬁrmed by
Sanger sequencing. The oligos (sgRNAs and Single-Stranded Oligo Donors
(ssODNs)) used in these experiments were listed in Supplementary Table 3.
SNP genotyping. SNP genotyping was performed by a standard Sanger
sequencing-based method. The regions containing mutations were PCR ampliﬁed
into B500 bp fragments using speciﬁc primers (Supplementary Table 3) and the
PCR products were puriﬁed using 1.5% agarose gel. A mixture of 10 ng puriﬁed
PCR products and 6 pmol primers was used for Sanger sequencing and the data
were analysed using CodonCode Aligner (V.5.0.2).
4C-seq analysis. The 4C experiments were carried out using a published
protocol51 with some modiﬁcations. For each assay, 1 107 cells were cross-linked
and quenched as in ChIP assays. Nuclei were isolated in a 50ml of lysis buffer
(10mM Tris-HCl pH 7.5, 10mM NaCl, 0.2% IGEPAL CA-630 detergent and
1 protease inhibitors). Subsequently, the nuclei were digested with 240 U NlaIII
enzyme (New England BioLabs Inc., R0215L) followed by an overnight in-nuclei
ligation with 4,000U T4 ligase (New England BioLabs Inc., M0202M) at 16 C.
The ligated DNA was de-crosslinked, puriﬁed, digested with 90U CviQI enzyme
(New England BioLabs Inc., R0639S) and circularized by 5,000U T4 ligase. The
circularized DNA (16 300 ng) was ampliﬁed with bait-speciﬁc inverse primers
(Supplementary Table 3), pooled and puriﬁed, followed by KAPA Hyper Prep
protocols.
Proteomics data processing. Recorded mass spectrometric (MS) ﬁles were ana-
lysed by MaxQuant software (version 1.3.5.7)52 using standard settings for dimethyl
or label-free quantiﬁcation analysis. All the ﬁles were searched against UniProtKB/
Swiss-Prot human database (generated from version 06-2012). Batch effects of the
pull-down data were removed using ‘Combat’ algorithm53. In dimethyl analysis,
some proteins were consistently quantiﬁed in the pulldowns of only one allele (Ref-
or Alt-allele) in two replicate experiments and the protein ratios can therefore not be
obtained from MaxQuant output. Therefore, we imputed the missing value in these
pulldown using ‘Replace missing values from normal distribution’ option in Perseus
software (version 1.3.9.18)54, which allows to further calculate protein ratios and
perform downstream analysis. TF interactors for each of the pulldown were
identiﬁed using ‘Signiﬁcance B’ function in Perseus software.
DNase I-seq ChIP-seq ATAC-seq data processing. Read mapping was
performed using BWA-ALN (DNase I-seq and ChIP-seq) and BWA-MEM
(ATAC-seq)55 against the hg19 reference human genome. PCR duplicates were
removed for further data analysis. Peak calling was carried out by MASC2 (ref. 56)
with default settings, except H3K27ac peaks were called using ‘broad’ option. Peaks
were called at a q-value cutoff of 0.01. Overlapping peaks were merged for each of
the different experiments before further analysis. Integrative Genomics Viewer57
was used to detect bi-allelic differential binding and hypersensitivity.
Targeted RNA-seq and RNA-seq data processing. Targeted RNA-seq data were
mapped to the hg19 reference human genome using BWA-MEM55. Integrative
Genomics Viewer57 was used to visualize the targeted RNA-seq data and detect
bi-allelic differential expression. The SYSCOL RNA-seq cohort was mapped to the
human reference genome sequence (GRCh37 autosomesþXþYþM) using GEM
mapper58. The reads with mapping quality o150 were excluded for further
analysis. The genes were annotated using Ensemble 75. The reads of the genes were
counted by ‘HTSeq’ framework59 and normalized using ‘DESeq’ package60.
Calculate signiﬁcance of the TF–SNP interactions. Importance of the TF–SNP
interaction in our screen study was considered by combining DHS of the SNPs
(read counts at the SNP position in 15 fetal large intestine tissues and 12 CRC cell
lines) and the interaction strength (Log2(fold change) of a TF between Ref and Alt
allele pulldown). The detailed P-value calculation was performed using z-test based
on following steps: (1) calculate average DHS (average DNase I-seq reads) of all the
116 loci in the DNase I-seq data from 15 fetal large intestine tissues and 12 CRC
cell lines, and then z-score transform the hypersensitivity data of these loci;
(2) calculate absolute Log2(fold change) of every TF–SNP interaction between Ref
and Alt alleles, and then z-score transform the absolute Log2(fold change) of all the
interactions; (3) average the z-scores of DHS and absolute Log2(fold change), and
convert the average z-scores into P-values based on normal statistical distribution.
eQTL analysis. The eQTL analysis was performed as described in a previous
publication61. Germline genotypes of these patients were genotyped on the Illumina
2.5M Exome v1.0 and imputed to 1000 genomes phase 3 release using IMPUTE2.
For cis-eQTL analysis, we normalized gene quantiﬁcation separately for healthy and
tumour samples. Technical covariates were discovered using the PEER programme62
and 20 PEER factors were used in normalization. The cis region was deﬁned as
±1Mb from the transcription start site for each gene. The associations between
genotypes and gene quantiﬁcation were obtained using the FastQTL software63.
4C-seq data processing. A reduced genome was generated by extracting the
sequences ﬂanking the NlaIII restriction sites (30 bp on each strand from the NlaIII
restriction sites to downstream) using the hg19 reference human genome in order
to improve the mappability of our 4C-seq data. Subsequently, the mappability of
the reduced sequences from each strand was evaluated and the uniquely mappable
NlaIII restriction sites were kept for downstream analysis.
The reads from each library were parsed based on the bait-speciﬁc primer
sequence and mapped to the reduced hg19 genome using BWA-ALN with the
default parameters. A Bioconductor package ‘r3Cseq’ (ref. 64) with 2.5 kb sliding
window was used to determine signiﬁcant interactions and calculate interaction
difference.
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Pathway annotation and GSEA analysis. TFs binding differentially to the 116
loci were annotated to PANTHER pathways using PANTHER Classiﬁcation
System65.
GSEA analysis66 was applied to identify the gene sets correlated to DCLK3
expression. The search was performed against hallmark gene sets in Molecular
Signatures Database (MSigDB, v5.1)67.
Data availability. Raw and processed LC–MS/MS data and sequencing data are
available at ProteomeXchange (http://www.ebi.ac.uk/pride/) and Gene Expression
Omnibus (https://www.ncbi.nlm.nih.gov/geo/) under the accession numbers
PXD004435 and GSE83968, respectively. The publically available data used in this
study were downloaded from Gene Expression Omnibus (https://www.ncbi.nlm.
nih.gov/geo/) using the following accession numbers: (1) H3K4me1 and H3K4me3
ChIP-seq: GSM1240111, GSM945304, GSM1208810, GSM1208811; (2) DNase
I-seq: GSM736493, GSM736600, GSM736500, GSM736587, GSM665815,
GSM665818, GSM665826, GSM701490, GSM701495, GSM701514, GSM701531,
GSM774213, GSM774214, GSM774217, GSM774220, GSM774228, GSM774233,
GSM817162, GSM817188; (3) TF ChIP-seq: GSM1010902, GSM1208683,
GSM1208642, GSM1240820, GSM803354, GSM1010847, GSM1208763,
GSM1010765, GSM1010790, GSM1010852, GSM1208598, GSM791411,
GSM791412, GSM782123, GSM1122306, GSM722708, GSM1122302,
GSM1122303. The detailed information of in-house generated and public data sets
used in this study are listed in Supplementary Table 4. All other remaining data are
available within the article and Supplementary Information ﬁles, or available from
the authors upon request.
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